Cyden Limited appears in FDA premarket notification records as the legal applicant for two Class II submissions received on the same date, 12 June 2026, and decided within days of each other in the autumn of that year. The devices are identified as Braun Aura 7 (6041) and Braun Aura 9 (6042), filed under product code OHT, the classification covering light-based over-the-counter hair removal. Both were reviewed by the General and Plastic Surgery panel and both carry a Special clearance type with a summary statement available. The company's own website describes it as a manufacturer of beauty technology based in Swansea, and the FDA filings list a Swansea address for the applicant contact. [1][2][3][4][5]

Documented FDA submissions and their scope

K261975 covers Braun Aura 7 (6041). The FDA record shows a receipt date of 12 June 2026 and a decision date of 30 September 2026, with decision code SESE, meaning substantially equivalent. The regulation is listed as 21 CFR 878.4810, described in the FDA letter as a laser surgical instrument for use in general and plastic surgery and in dermatology, and the device is assigned regulatory class II. The submission was not reviewed by a third party, is not a combination product, and no predetermined change control plan was authorized. [1][3][4]

K261977 covers Braun Aura 9 (6042). Its receipt date matches at 12 June 2026, and the decision date is 25 September 2026, again SESE. The product code, regulation number, advisory committee and clearance type match the companion filing, and a summary statement is recorded. Both entries appear in the supplied collection under the 510(k) pathway with a decision count of two SESE decisions; that count describes the supplied filings only and is not a measure of company output or safety record. [2][9]

Applicant identity and the brand question

The applicant name is not identical across the two records: K261975 lists CyDen Limited and K261977 lists Cyden Limited. The FDA clearance letter for K261975 is addressed to CyDen Limited, attention Matthew Silverberg, Regulatory Engineer, at Block A, Bay Studios Business Park, Fabian Way, Swansea, SA1 8QB, United Kingdom. The same individual appears as contact in both FDA.report entries. That address is a filing address and should not be read as a verified corporate headquarters. [1][2][4][7]

The device names carry the Braun name, but the cited records do not establish any parent, licensor or brand-owner relationship between Cyden and any other entity. The FDA applicant of record is Cyden; the commercial arrangement behind the naming is unknown from these sources. Readers should treat the applicant identity and the brand name as separate facts rather than inferring ownership. [1][2][4]

Company description as published by the company

Cyden's own website describes the firm as a manufacturer of beauty technology and states that it transforms professional aesthetic technologies into at-home devices. The same publisher states the company has over 40 years of experience in energy-based skin solutions and lists a Swansea office address at the same Bay Studios Business Park location that appears in the FDA filings. A separate company page says the business was founded in Swansea, where its headquarters remain, and describes manufacturing facilities in the UK and China. These are company statements, not independently verified facts. [5][6]

The company page also states that Cyden was the first IPL manufacturer to introduce fully recyclable packaging. No clinical outcome data, certification or independent validation for these claims appears in the public documents, and no efficacy figures should be attached to the Aura devices on the strength of marketing text. [6]

What the record does and does not show

The supplied collection contains two linked 510(k) records and no recall entries in the sample provided. An empty recall sample is not evidence that no recalls exist; post-market history for these devices is unknown from these sources. Likewise, the two clearances say nothing about sales volume, market share, pricing or commercial availability, and the collection counts are a snapshot of supplied filings rather than a total portfolio. [1][2][3]

Third-party aggregators repeat the same core fields as the FDA records, including product code OHT, regulation 878.4810, device class 2 and the SESE decisions, and one aggregator notes that source data can change and that critical regulatory decisions should be verified against the official FDA source. Innolitics lists an earlier OHT-coded clearance, k143003 for the iPulse SmoothSkin Gold Hair Removal System, in its related-records context; that entry is not part of the supplied company collection and is not attributed here to Cyden. [7][8][9]